In its weekly update today, the US Centers for Disease Control and Prevention (CDC) reported 40 more measles cases today, ...

Shionogi will pay BioVersys $6.3 million for developing BV500, BioVersys's drug candidate for non-tuberculous mycobacteria.

Compared with flu vaccine recipients, those given the RSV or shingles vaccine had 18% to 37% lower odds of receiving a ...

Relative to before the pandemic, the number of vaccinated participants fell 10% among children and 4% in adults in pandemic ...